Great find jonzobot.

Perhaps this is an issue of when management is not capable of finding funding they have to deal with an ineffective CRO?

At least it does not rule out that apabetalone was not effective because it wasn't tested.

Too bad that RVX PR did not inform shareholders of the situation.

Toinv